New blood thinner tested for COVID-19 clot prevention

NCT ID NCT07134738

Completed Prevention Sponsor: Avexima Diol LLC Source: ClinicalTrials.gov ↗

First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This completed study looked at whether a drug called Dimolegin can safely prevent blood clots in adults hospitalized with moderate COVID-19. A total of 184 participants took a 60 mg tablet once daily as part of their regular care. The main goal was to check for serious bleeding and other side effects.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Dimolegin (oral tablet, 60 mg once daily)
What this could lead to: If results are positive, Dimolegin could offer a new option to prevent dangerous blood clots in hospitalized COVID-19 patients.
What could go wrong: This was a small, non-interventional study without a comparison group, so it cannot prove effectiveness. The main risk was bleeding, which was closely monitored.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for COVID-19 are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

COVID-19 thrombotic disease prevention target

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

COVID-19

Contacts and locations

Locations

Infectious Diseases Clinical Hospital No. 1

Moscow, Russia
Infectious Diseases Hospital No. 2

Sochi, Russia
Regional Clinical Hospital No. 3

Chelyabinsk, Russia
Regional Infectious Diseases Clinical Hospital

Yaroslavl, Russia
Republican Clinical Hospital named after Professor A.F. Agafonov

Kazan', Russia
Tomsk Regional Hospital

Tomsk, Russia

More trials for these conditions

Other studies related to the condition(s) this trial covers.